bluebird bio, Inc.

NasdaqGS BLUE

bluebird bio, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2024: 174,822,500

bluebird bio, Inc. Shares (Diluted, Weighted) is 174,822,500 for the Trailing 12 Months (TTM) ending September 30, 2024, a 72.13% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

bluebird bio, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2023 was 101,567,000, a 34.75% change year over year.
bluebird bio, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2022 was 75,374,000, a 11.88% change year over year.
bluebird bio, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2021 was 67,369,750, a 13.43% change year over year.
bluebird bio, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2020 was 59,392,250, a 7.92% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqGS: BLUE

bluebird bio, Inc.

CEO	Mr. Andrew Obenshain
IPO Date	June 19, 2013
Location	United States
Headquarters	60 Binney Street
Employees	375
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years